Exceptional Response in BRAF p.V600E-Mutant Enteric-Type Adenocarcinoma of the Lung With Cutaneous Spread: A Case Report.

BRAF p.V600E Case report Cutaneous metastases Dabrafenib plus trametinib Enteric-type lung adenocarcinoma Non–small cell lung cancer

Journal

JTO clinical and research reports
ISSN: 2666-3643
Titre abrégé: JTO Clin Res Rep
Pays: United States
ID NLM: 101769967

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 19 09 2023
revised: 17 10 2023
accepted: 28 10 2023
medline: 21 12 2023
pubmed: 21 12 2023
entrez: 21 12 2023
Statut: epublish

Résumé

Enteric-type adenocarcinoma of the lung (lung-ETAC) is a rare form of lung cancer with histologic similarities to colorectal cancer, with aggressive behavior and unfavorable prognosis. An 81-year-old man presented with discolored skin lesions on the chest and abdomen. After comprehensive evaluation, including skin biopsy and molecular profiling, the patient was diagnosed with having lung-ETAC with a BRAF p.V600E mutation. Treatment with dabrafenib and trametinib initially resulted in positive results, with improvement in skin lesions and overall clinical condition. Nevertheless, approximately 6 months after, the disease had progression with new skin lesions reappearing. We reported a unique case of a patient with BRAF p.V600E-mutant lung-ETAC with metastatic skin lesions achieving complete cutaneous response after targeted treatment with dabrafenib and trametinib, highlighting the potential for targeted therapy in patients with lung-ETAC harboring a BRAF p.V600E mutation.

Sections du résumé

Background UNASSIGNED
Enteric-type adenocarcinoma of the lung (lung-ETAC) is a rare form of lung cancer with histologic similarities to colorectal cancer, with aggressive behavior and unfavorable prognosis.
Case Presentation UNASSIGNED
An 81-year-old man presented with discolored skin lesions on the chest and abdomen. After comprehensive evaluation, including skin biopsy and molecular profiling, the patient was diagnosed with having lung-ETAC with a BRAF p.V600E mutation. Treatment with dabrafenib and trametinib initially resulted in positive results, with improvement in skin lesions and overall clinical condition. Nevertheless, approximately 6 months after, the disease had progression with new skin lesions reappearing.
Conclusions UNASSIGNED
We reported a unique case of a patient with BRAF p.V600E-mutant lung-ETAC with metastatic skin lesions achieving complete cutaneous response after targeted treatment with dabrafenib and trametinib, highlighting the potential for targeted therapy in patients with lung-ETAC harboring a BRAF p.V600E mutation.

Identifiants

DOI: 10.1016/j.jtocrr.2023.100597 PMID: 38124787 PMC: PMC10730365
pubmed: 38124787
doi: 10.1016/j.jtocrr.2023.100597
pii: S2666-3643(23)00140-6
pmc: PMC10730365
doi:

Types de publication

Case Reports

Langues

eng

Pagination

100597

Informations de copyright

© 2023 The Authors.

Auteurs

Marco Sposito (M)

Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy.

Ilaria Mariangela Scaglione (IM)

Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy.

Serena Eccher (S)

Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy.

Luca Pasqualin (L)

Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy.

Alice Avancini (A)

Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy.
Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.

Chiara Colato (C)

Section of Pathology, Department of Diagnostic and Public Health, University of Verona, Verona, Italy.

Paolo Rosina (P)

Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.

Michele Simbolo (M)

Section of Pathology, Department of Diagnostic and Public Health, University of Verona, Verona, Italy.

Anna Caliò (A)

Section of Pathology, Department of Diagnostic and Public Health, University of Verona, Verona, Italy.

Aldo Scarpa (A)

Section of Pathology, Department of Diagnostic and Public Health, University of Verona, Verona, Italy.

Michele Milella (M)

Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy.

Sara Pilotto (S)

Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy.

Lorenzo Belluomini (L)

Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy.

Classifications MeSH